Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission

Paloma Pandhi¹, Jozine M. ter Maaten¹, Johanna E. Emmens¹, Joachim Struck², Andreas Bergmann², John G. Cleland³, Michael M. Givertz⁴, Marco Metra⁵, Christopher M. O’Connor⁶, John R. Teerlink⁷, Piotr Ponikowski⁸, Gad Cotter⁹, Beth Davison⁹, Dirk J. van Veldhuisen¹, and Adriaan A. Voors¹*

¹Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ²Sphingotec GmbH, Hennigsdorf, Germany; ³Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK; ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; ⁵University of Brescia, Brescia, Italy; ⁶Inova Heart and Vascular Institute, Falls Church, VA, USA; ⁷University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; ⁸Medical University, Clinical Military Hospital, Wroclaw, Poland; and ⁹Momentum Research, Durham, NC, USA

Received 17 July 2019; revised 4 October 2019; accepted 28 October 2019; online publish-ahead-of-print 3 December 2019

Aims

Recently, bio-adrenomedullin (bio-ADM) was proposed as a congestion marker in heart failure (HF). In the present study, we aimed to study whether bio-ADM levels at discharge from a hospital admission for worsening HF could provide additional information on (residual) congestion status, diuretic dose titration and clinical outcomes.

Methods and results

Plasma bio-ADM was measured in 1236 acute HF patients in the PROTECT trial at day 7 or discharge. Median discharge bio-ADM was 33.7 [21.5–61.5] pg/mL. Patients with higher discharge bio-ADM levels were hospitalised longer, had higher brain natriuretic peptide levels, and poorer diuretic response (all \( P < 0.001 \)). Bio-ADM was the strongest predictor of discharge residual congestion (clinical congestion score \( > 3 \)) (odds ratio 4.35, 95% confidence interval 3.37–5.62; \( P < 0.001 \)). Oedema at discharge was one of the strongest predictors of discharge bio-ADM (\( \beta = 0.218; P < 0.001 \)). Higher discharge loop diuretic doses were associated with a poorer diuretic response during hospitalisation (\( \beta = 0.187; P < 0.001 \)) and higher bio-ADM levels (\( \beta = 0.084; P = 0.020 \)). High discharge bio-ADM levels combined with higher use of loop diuretics were independently associated with a greater risk of 60-day HF rehospitalisation (hazard ratio 4.02, 95% confidence interval 2.23–7.26; \( P < 0.001 \)).

Conclusion

In hospitalised HF patients, elevated pre-discharge bio-ADM levels were associated with higher discharge loop diuretic doses and reflected residual congestion. Patients with combined higher bio-ADM levels and higher loop diuretic use at discharge had an increased risk of rehospitalisation. Assessment of discharge bio-ADM levels may be a readily applicable marker to identify patients with residual congestion at higher risk of early hospital readmission.

Keywords

Bio-adrenomedullin • Loop diuretics • Acute heart failure

Introduction

Acute heart failure (AHF) is characterised by fluid overload and signs and symptoms of congestion in 95% of the patients.¹ As a result, decongestive therapy using diuretics is the primary aim of treatment.¹ Despite receiving diuretic therapy, a significant number of patients are still discharged with one or more signs of residual congestion, which is independently associated with worse post-discharge outcomes.²–⁴ However, pre-discharge assessment of residual congestion is notoriously difficult, and current clinical
assessments such as rales, oedema, jugular venous pressure (JVP), and chest radiographs have high inter-observer variability.\(^4\)\(^\text{–}^6\) Hence, there is an increasing need to assess congestion status objectively for better discharge planning including loop diuretic dose titration and post-discharge follow-up.

Recently, biologically active adrenomedullin (bio-ADM) was proposed as a congestion marker.\(^5\)\(^\text{–}^9\) Adrenomedullin (ADM) is a 52-amino acid vasodilatory peptide hormone secreted by endothelial and smooth muscle cells of blood vessels and is involved in blood pressure regulation and maintenance of vascular integrity.\(^6\)(\(^\text{–}^9\)) ADM is produced in an inactive glycine-extended form after proteolytic cleavage of a large precursor hormone pro-adrenomedullin (pro-ADM).\(^10\) About 5–20% of this inactive hormone is converted into bio-ADM.\(^7\)\(^\text{–}^11\) Bio-ADM levels are elevated in conditions that reflect fluid overload, vascular leakage, and oedema, such as sepsis, and AHF, and is predictive of adverse short-term outcomes.\(^6\)\(^,^9\)\(^\text{–}^15\) Emerging evidence suggests that baseline bio-ADM levels are correlated with the severity of congestion at admission and during/after hospitalisation in AHF patients.\(^8\)\(^,^9\)\(^\text{–}^15\) However, as a potential congestion marker, the role of using pre-discharge bio-ADM levels to monitor residual congestion status and accordingly optimize decongestive therapies remains undescribed. Therefore, in the present study we aimed to investigate the hypothesis that elevated discharge bio-ADM levels are associated with (residual) congestion and increased loop diuretic use at discharge. Furthermore, by assessing the additive prognostic value of bio-ADM on top of loop diuretic doses, we aimed to investigate their combined ability for identifying inadequately decongested patients at a higher risk of adverse outcomes.

**Methods**

**Study design and procedures**

Study design and main results of the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial have been published elsewhere.\(^16\)\(^\text{–}^17\) Briefly, in the multicentre, randomised, double-blind placebo-controlled PROTECT trial, 2033 patients with AHF were randomised to rolofylline or placebo in a 2:1 ratio. Eligible patients had brain natriuretic peptide (BNP) levels ≥500 pg/mL or N-terminal pro brain natriuretic peptide levels ≥2000 pg/mL, ongoing intravenous (IV) loop diuretic therapy and dyspnoea at rest or with minimal physical activity and impaired renal function. Overall study results were neutral.\(^17\) All enrolled patients provided written informed consent. The trial was conducted according to the Declaration of Helsinki and all local and national ethics committees approved the protocol.

In the PROTECT trial, signs and symptoms of heart failure (HF) and other biochemical measurements are available at least at baseline, discharge and at days 2, 7 and 14. Body weight was measured from baseline until day 4. Creatinine clearance was calculated using the Cockcroft–Gault formula.\(^17\) Plasma bio-ADM levels were measured in patient EDTA samples using a novel immunoassay (Sphingotec GmbH, Henningsdorf, Germany). Measurements were available at baseline (n = 1562) and at discharge (if discharge occurred before day 7), otherwise it was measured on day 7 (n = 1236).\(^17\)\(^,^18\) BNP levels were measured using a highly sensitive single molecule counting (SMC™) technology (RUO, Erenna® Immunoassay System; Singulex Inc., Alameda, CA, USA). Further information on biomarkers measured in the PROTECT trial has been described previously.\(^18\)\(^,^19\)

**Study population and assessments**

The current study is a retrospective analysis of the PROTECT trial. A clinical congestion score (CCS) was calculated by adding up the individual scores of JVP (0 to 2), orthopnoea (0 to 3) and peripheral oedema (0 to 3), yielding a maximum score of 8.\(^2\)\(^,^20\) Patients with missing CCS data at day 7 (n = 461) were excluded from all analyses involving this variable. Diuretic response was calculated as weight change (in kg) until day 4 per 40 mg of IV furosemide administered in the first 72 h of hospital admission (or equivalents – bumetanide: 1 mg, torsemide: 20 mg). Discharge loop diuretic doses were calculated by adjusting the doses according to frequency, route of administration and furosemide equivalents. Final discharge diuretic doses were calculated as [IV/2 = oral dose]. Total cumulative diuretic doses till day 7 were calculated as [IV + (0.5 x oral dose)], adjusting for bioavailability. Loop diuretic doses were available in 1497 subjects at discharge. From the initial intention-to-treat study population of 2033 subjects, patients who underwent dialysis through day 4, had weight loss >20 kg or had missing values for day 7 bio-ADM levels (total n = 803) were excluded, resulting in a final study population of 1230 patients (online supplementary Figure S1). The included patient population was comparable to the excluded patient population (online supplementary Table S1).

**Statistical analysis**

Continuous variables are summarised as means (± standard deviation) or as median [interquartile range] as appropriate, and categorical variables are presented as number (percentage). Differences between tertiles of bio-ADM were tested using analysis of variance (ANOVA) or Kruskal–Wallis test for continuous variables and Pearson χ² for categorical variables. Normality was assessed using histograms and normal quantile–quantile plots. Non-normally distributed variables were natural log-transformed. Associations between clinical variables and residual congestion (defined as CCS > 3) at discharge were assessed using a logistic regression model. Multivariable linear regression models were constructed using backward elimination to identify predictors of discharge bio-ADM levels and loop diuretic doses. All variables with a P-value <0.10 from univariable analyses were included.

Cox proportional hazards regression analysis was performed to investigate the prognostic ability of bio-ADM levels individually and combined with loop diuretic doses for endpoints. Multivariable models were adjusted in model 1 for rolofylline treatment and for baseline variables from the PROTECT model published previously.\(^21\) This model includes age, previous HF hospitalisation, peripheral oedema, systolic blood pressure, serum sodium, log blood urea nitrogen, log creatinine and albumin. Model 2 was adjusted for baseline log bio-ADM levels and day 7 log BNP levels in addition to model 1. Proportional hazards assumptions were checked using Schoenfeld residuals and log–log plots. Kaplan–Meier survival estimates were used to investigate the prognostic ability of discharge bio-ADM levels combined with loop diuretic doses. Differences between groups were tested using a log-rank test. Two-tailed tests were used and a
Bio-ADM, residual congestion and outcomes in AHF

Results
Baseline characteristics
Baseline characteristics according to tertiles of discharge bio-ADM levels are presented in Table 1. Median bio-ADM levels were 33.7 [21.5–61.5] pg/mL at discharge. Higher discharge bio-ADM levels were associated with a longer duration of hospitalisation, poorer diuretic response, worsening renal function and higher BNP levels at discharge (all \( P < 0.001 \)). Furthermore, loop diuretic use and signs and symptoms of residual congestion, such as a high congestion score, orthopnoea, rales, JVP and oedema were more prevalent across increasing tertiles of bio-ADM (all \( P < 0.006 \)).

To further elucidate the relation between bio-ADM levels and loop diuretic doses at discharge, patients were divided into groups based on the respective medians (Table 2). Patients with elevated discharge bio-ADM levels combined with increased loop diuretic usage reflected a more diseased profile, as indicated by elevated levels of BNP and worsening renal function biomarkers (all \( P < 0.001 \)). Interestingly, only few patients with high bio-ADM levels were receiving lower doses of loop diuretics, as this was the smallest of the four groups. Similar patterns in clinical characteristics were observed when patients were divided according to change in bio-ADM levels from baseline to discharge in combination with loop diuretic dosing (online supplementary Table S2). Trends across tertiles of congestion score at discharge were comparable to that of bio-ADM (online supplementary Table S3).

Predictors of bio-ADM levels, loop diuretic doses, and residual congestion at discharge
Taking the initial population of 1230 patients, after dropping missing values for discharge bio-ADM levels, 691 patients out of 1230 (56.2%) were discharged after day 7. In a multivariable linear regression model for predictors of discharge bio-ADM levels, oedema (\( \beta = 0.218, P < 0.001 \)) was the strongest predictor of bio-ADM (adjusted \( r^2 = 0.312 \)) (Table 3). In this model, higher discharge bio-ADM levels were also associated with higher BNP levels and serum creatinine at discharge and a history of diabetes and atrial fibrillation. In a univariable logistic regression model, bio-ADM was the strongest predictor of residual congestion (as indicated by a CCS score \( > 3 \)) at discharge (odds ratio 4.35, 95% confidence interval (CI) 3.37–5.62; \( P < 0.001 \)) (online supplementary Table S4). In a multivariable linear regression model for predictors of loop diuretics, higher loop diuretic use at discharge was independently associated with a poorer diuretic response during hospitalisation (\( \beta = 0.187; P < 0.001 \)) and higher discharge bio-ADM levels (\( \beta = 0.084; P = 0.020 \)) (adjusted \( r^2 = 0.261 \)) (online supplementary Table S5).

Bio-ADM levels, residual congestion, and discharge diuretic doses as predictors of outcomes in acute heart failure
Log bio-ADM at discharge was independently associated with an increased risk of all-cause mortality (hazard ratio (HR) 1.58 per log increase, 95% CI 1.22–2.05; \( P = 0.001 \)), and HF rehospitalisation (HR 1.42 per log increase, 95% CI 1.10–1.84; \( P = 0.008 \)), in contrast to baseline bio-ADM levels (Table 4). The curves for 180-day mortality and 60-day readmission according tertiles of discharge bio-ADM levels have been presented in online supplementary Figures S2 and S3. The Kaplan–Meier curves for 60-day readmission due to HF for the combined groups of bio-ADM and loop diuretic doses at discharge are presented in Figure 1. Higher loop diuretic doses were independently associated with increased HF rehospitalisation, irrespective of bio-ADM levels (high or low; Figure 1 and online supplementary Table S6). Interestingly, higher bio-ADM levels combined with higher use of loop diuretics was associated with a four times higher risk of rehospitalisation compared to the reference group (HR 4.02 per log increase, 95% CI 2.23–7.26; \( P < 0.001 \)). The association remained significant even after adjusting for the baseline PROTECT model, baseline log bio-ADM and day 7 log BNP levels (online supplementary Table S6).

Discussion
In this study, we showed that higher levels of pre-discharge plasma bio-ADM levels are associated with more signs and symptoms of residual congestion and increased use of loop diuretics at discharge. Elevated pre-discharge bio-ADM levels had additive prognostic value on top of higher doses of loop diuretics to predict risk of early HF hospital readmissions. Thus, bio-ADM levels measured before discharge may be a valuable indicator of those patients that were not sufficiently decongested and consequently have a higher risk of readmission due to HF.

Role of bio-ADM as a congestion marker
Release of ADM is stimulated by volume overload as a protective response to limit further vascular leakage and the resulting tissue and interstitial fluid accumulation, by maintaining the vascular endothelial barrier function.6,10 Bio-ADM levels are elevated in AHF, a condition characterized by volume overload, and are reflective of congestion.6,8,9,11 We recently showed that bio-ADM levels measured during hospital admission or an episode of worsening signs and/or symptoms of HF were independently associated with severity of congestion, even after adjusting for other variables associated with congestion.8,9 In the current study, we expanded on these findings and studied the clinical correlates associated with elevated pre-discharge bio-ADM levels, increased use of loop diuretic doses and the prognostic ability of discharge bio-ADM levels combined with loop diuretic doses.

Recent studies have demonstrated that inadequate decongestion at the time of discharge still remains a prevalent issue in AHF.
Table 1  Baseline characteristics according to tertiles of day 7 or discharge bio-adrenomedullin levels

| Variables                      | Tertile 1 | Tertile 2 | Tertile 3 | P-value |
|--------------------------------|-----------|-----------|-----------|---------|
| Patients, n                    | 411       | 409       | 410       |         |
| Bio-ADM day 7 (pg/mL)          | 17.6 [12.7–21.5] | 33.7 [29.0–40.3] | 80.5 [60.5–124.3] | <0.001 |
| **Demographics**               |           |           |           |         |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |
| Male sex                       | 267 (65.0) | 262 (64.1) | 278 (67.8) | 0.500  |
| Age (years)                    | 70.9 (11.1) | 71.3 (11.1) | 69.7 (11.1) | 0.099  |
| LVEF at baseline (%)           | 32.5 (12.3) | 32.3 (12.1) | 32.4 (13.8) | 0.980  |
| **Clinical profile**           |           |           |           |         |
| LOS (days)                     | 7.0 [6.0–12.0] | 8.0 [6.0–14.0] | 10.0 [7.0–16.0] | <0.001 |
| Improvement in dyspnoea        | 1.0 [0.0–2.0] | 1.0 [1.0–2.0] | 2.0 [1.0–4.0] | <0.001 |
| NYHA class III/IV              | 134 (36.2) | 169 (44.9) | 214 (58.2) | <0.001 |
| Orthopnoea ≥2                  | 86 (22.4) | 131 (34.3) | <0.001    |

Values are presented as mean (± standard deviation), median ([interquartile range], or n (%) wherever appropriate.

Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.

ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AI, aldosterone inhibitor; ARB, angiotensin receptor blocker; bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CCB, calcium channel blocker; CCS, clinical congestion score; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease; IV, intravenous; JVP, jugular venous pressure; LOS, length of stay; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.

*Maximum score is 8, values are lower than usual as patients with missing values of components of the score were not dropped.

© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
patients, which is associated with a higher risk of readmission and mortality. Moreover, pre-discharge assessment of residual congestion is still suboptimal. Though measurement of right atrial pressure and pulmonary capillary wedge pressure using cardiac catheterisation is considered the gold standard, this technique is highly invasive and not used routinely. Non-invasive assessments such as JVP, oedema, and rales are subject to inter- and intra-observer variability, lack standardisation, and a decreasing number of medical professionals are sufficiently skilled to assess them. Thus, biomarkers are of interest for assessing congestion as they are objective, and easily measurable. Though natriuretic peptides are commonly used to assess congestion, their production is mainly triggered by increased cardiac stretch and pressure during a state of volume overload. In contrast, bio-ADM is stimulated to maintain vascular integrity in response to tissue congestion. Therefore, though both markers provide information on congestion status, the distinct mechanisms of production suggest that BNP may be a marker better suited for circulatory congestion and bio-ADM for tissue congestion. In our study, bio-ADM at discharge was associated with BNP levels and loop diuretic doses at discharge. However, BNP levels were not associated with loop diuretic doses; therefore, bio-ADM may be of additive value on top of natriuretic peptides to assess pre-discharge residual congestion status. The utility of bio-ADM further needs to be validated using more invasive diagnostics studies such as lung ultrasound and cardiac catheterisation, which were unfortunately not available in this study.

### Bio-ADM, loop diuretics, and risk of rehospitalisation

In recent studies, bio-ADM was shown to be predictive of adverse short-term outcomes in conditions such as AHF and sepsis. In the current study, higher bio-ADM levels combined with increased use of loop diuretics were associated with a four times higher risk of readmission compared to the reference group, even after adjusting for discharge BNP and baseline bio-ADM levels. When combined with congestion score and BNP levels, low bio-ADM levels may help to identify patients with resolved congestion and an even lower risk of readmission, who

| Table 2 Baseline characteristics according to combined groups of day 7 bio-adrenomedullin levels (high or low) and loop diuretic doses at discharge (high or low) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variables                       | 1: Low bio-ADM  | 2: Low bio-ADM  | 3: High bio-ADM | 4: High bio-ADM | P-value         |
|                                 | + low dose      | + high dose     | + low dose      | + high dose     |                 |
| Patients, n                     | 259             | 206             | 188             | 278             |                 |
| Bio-ADM day 1 (pg/mL)           | 23.9 [16.0–33.7] | 27.9 [19.2–40.1] | 66.9 [42.6–99.5] | 74.0 [45.9–121.1] |                 |
| Bio-ADM day 7 (pg/mL)           | 20.9 [14.4–26.1] | 19.6 [14.2–25.1] | 51.7 [37.9–72.2] | 60.3 [43.0–90.6] |                 |
| Demographics                    |                 |                 |                 |                 |                 |
| Male sex                        | 152 (58.7)      | 147 (71.4)      | 114 (60.6)      | 197 (70.9)      | 0.003           |
| Age (years)                     | 70.8 (10.9)     | 70.1 (11.6)     | 71.9 (10.7)     | 70.7 (11.0)     | 0.460           |
| White                           | 254 (98.1)      | 197 (95.6)      | 183 (97.3)      | 257 (92.4)      | 0.008           |
| LVEF at baseline (%)            | 34.5 (12.6)     | 29.8 (12.0)     | 33.0 (11.6)     | 30.3 (13.7)     | 0.012           |
| Clinical profile                |                 |                 |                 |                 |                 |
| LOS (days)                      | 7.0 [6.0–13.0]  | 7.0 [4.0–9.0]   | 8.0 [7.0–15.0]  | 8.5 [6.0–14.0]  | <0.001          |
| CCSa                           | 1.0 [0.0–2.0]   | 1.0 [0.0–2.0]   | 2.0 [0.0–3.0]   | 2.0 [1.0–3.0]   | <0.001          |
| Improvement in dyspnoea         | 224 (96.1)      | 177 (93.7)      | 163 (92.6)      | 220 (85.6)      | <0.001          |
| NYHA class III/IV               | 92 (40.2)       | 60 (32.4)       | 81 (46.8)       | 131 (52.8)      | <0.001          |
| Study medications               |                 |                 |                 |                 |                 |
| Rolofylline 30 mg               | 156 (60.2)      | 140 (68.0)      | 130 (69.1)      | 201 (72.3)      | 0.025           |
| Loop diuretics at discharge     | 40.0 [40.0–40.0] | 80.0 [80.0–120.0] | 40.0 [24.5–40.0] | 80.0 [80.0–160.0] | <0.001          |
| Total diuretics until day 7 (IV + oral) | 270.0 [180.0–399.4] | 520.0 [370.0–760.0] | 300.0 [200.0–480.0] | 690.0 [440.0–1165.0] | <0.001          |
| Diuretic response (kg/40mg furosemide) | −0.5 [−1.0 to −0.2] | −0.3 [−0.6 to −0.1] | −0.6 [−1.0 to −0.3] | −0.3 [−0.6 to −0.1] | <0.001          |
| Biomarkers                      |                 |                 |                 |                 |                 |
| BNP (pg/mL)                     | 196.5 [108.0–333.0] | 204.0 [132.0–389.0] | 291.0 [147.5–557.5] | 319.5 [193.0–660.5] | <0.001          |
| Creatinine (mg/dL)              | 1.3 [1.0–1.5]   | 1.3 [1.1–1.7]   | 1.5 [1.1–2.0]   | 1.6 [1.3–2.1]   | <0.001          |
| eGFR (mL/min/1.73 m²)           | 49.6 [37.0–65.6] | 48.0 [34.2–62.0] | 40.4 [30.6–57.5] | 40.6 [31.2–55.6] | <0.001          |
| Albumin (g/dL)                  | 4.0 [3.7–4.3]   | 4.0 [3.7–4.3]   | 3.9 [3.6–4.1]   | 3.9 [3.6–4.1]   | <0.001          |
| BUN (mg/dL)                     | 28.0 [22.0–36.0] | 33.0 [25.0–42.0] | 34.0 [25.0–46.0] | 39.0 [29.0–55.0] | <0.001          |

Values are presented as mean (± standard deviation), median [interquartile range], or n (%) wherever appropriate.

Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.

bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CCS, clinical congestion score; eGFR, estimated glomerular filtration rate; IV, intravenous; LOS, length of stay; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Maximum score 8, values are lower than usual as patients with missing values of components of the score were not dropped.
could therefore be safely discharged. On the other hand, higher bio-ADM levels may help detect patients that are inadequately decongested, and if the patients are already receiving optimal loop diuretic doses or are resistant to diuretic therapy, re-assessment of treatment may be warranted. In these patients, the physician can then consider extending hospital stay and selecting an alternative treatment strategy, such as increasing the diuretic dose further, using IV loop diuretics, changing to another loop diuretic type (e.g. torsemide), or combination of loop diuretic with either a thiazide diuretic or an aldosterone antagonist. As PENK levels rise faster than creatinine during renal damage, the marker can be used to identify patients who do not tolerate intensification of diuretic treatment based on bio-ADM levels. In these patients, surrogate treatment strategies such as ultrafiltration, hypertonic saline infusion, rololofylline or vasopressin antagonist tolvaptan might be of benefit.

Interestingly, patients with high bio-ADM levels receiving high loop diuretic doses formed the largest patient group in our study, while patients with high bio-ADM levels receiving lower doses of loop diuretics at discharge composed the smallest group. This

### Table 3 Multivariable model for predictors of discharge bio-adrenomedullin levels

| Variables                        | Log bio-ADM at discharge<sup>a</sup> | Standardized β | T-value | P-value |
|----------------------------------|--------------------------------------|----------------|---------|---------|
| Oedema                           | 0.218                                | 8.04           | <0.001  |
| Log BNP                          | 0.209                                | 7.61           | <0.001  |
| Log creatinine                   | 0.169                                | 6.40           | <0.001  |
| History of DM                    | 0.111                                | 4.27           | <0.001  |
| History of AF                    | 0.113                                | 4.22           | <0.001  |
| Dyspnoea on exertion             | 0.098                                | 3.73           | <0.001  |
| Digoxin                          | 0.062                                | 2.31           | 0.021   |
| History of COPD                  | 0.053                                | 2.09           | 0.037   |
| Albumin                          | −0.060                               | −2.22          | 0.026   |
| Sodium                           | −0.060                               | −2.32          | 0.021   |
| Log total cholesterol            | −0.143                               | −5.11          | <0.001  |

Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.

AF, atrial fibrillation; bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.

<sup>a</sup>n = 1080, r² = 0.319, adjusted r² = 0.312.

### Table 4 Cox regression analyses for bio-adrenomedullin levels for 180-day mortality and 60-day heart failure rehospitalisation

| Outcome                  | Events, n (%) | Log bio-ADM levels | Univariable Cox | Model 1<sup>a</sup> | Model 2<sup>b</sup> |
|--------------------------|---------------|--------------------|-----------------|---------------------|---------------------|
|                          |               |                    | HR (95% CI) per log increase | P-value | HR (95% CI) per log increase | P-value | HR (95% CI) per log increase | P-value |
| 180-day mortality        |               |                    |                 |                     |                     |
| Day 1                    | 270/1556 (17.4)| Day 1              | 1.49 (1.30–1.70) | <0.001              | 1.25 (1.07–1.45)    | 0.004              |
| Day 7                    | 186/1230 (15.1)| Day 7              | 1.78 (1.53–2.08) | <0.001              | 1.47 (1.24–1.75)    | <0.001             |
| Difference day 1 to 7    | 186/1230 (15.1)| Difference day 1 to 7| 1.44 (1.21–1.70) | <0.001              | 1.22 (1.02–1.45)    | 0.027              |
| 60-day HF rehospitalisation |               |                    |                 |                     |                     |
| Day 1                    | 230/1556 (14.8)| Day 1              | 1.10 (0.95–1.27) | 0.199               | 1.02 (0.87–1.20)    | 0.783              |
| Day 7                    | 187/1230 (15.2)| Day 7              | 1.35 (1.16–1.58) | <0.001              | 1.28 (1.08–1.51)    | 0.005              |
| Difference day 1 to 7    | 187/1230 (15.2)| Difference day 1 to 7| 1.11 (0.96–1.29) | 0.171               | 1.02 (0.87–1.19)    | 0.840              |

bio-ADM, bio-adrenomedullin; CI, confidence interval; HF, heart failure; HR, hazard ratio.

<sup>a</sup>Model 1 was adjusted for rololofylline treatment and for baseline variables from the PROTECT model published previously that included age, previous HF hospitalisation, peripheral oedema, systolic blood pressure, serum sodium, log blood urea nitrogen, log creatinine and albumin.

<sup>b</sup>Model 2 was adjusted for day 1 log bio-ADM levels and day 7 log BNP levels in addition to model 1.

© 2019 The Authors. *European Journal of Heart Failure* published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
In hospitalised HF patients, elevated discharge bio-ADM levels were associated with higher discharge loop diuretic doses and reflected residual congestion. Patients with both higher bio-ADM levels and higher loop diuretic doses at discharge had an increased risk of early hospital readmission for worsening HF. Assessment of discharge bio-ADM may be a readily applicable marker to identify patients with residual congestion at higher risk of early hospital readmission. Future prospective studies need to establish whether bio-ADM can be used to guide time of discharge and loop diuretic doses pre- and post-discharge.

Conclusions

In hospitalised HF patients, elevated discharge bio-ADM levels were associated with higher discharge loop diuretic doses and reflected residual congestion. Patients with both higher bio-ADM levels and higher loop diuretic doses at discharge had an increased risk of early hospital readmission for worsening HF. Assessment of discharge bio-ADM may be a readily applicable marker to identify patients with residual congestion at higher risk of early hospital readmission. Future prospective studies need to establish whether bio-ADM can be used to guide time of discharge and loop diuretic doses pre- and post-discharge.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Diagram showing study populations after excluding patients.

Figure S2. Kaplan–Meier curve for 180-day mortality for tertiles of discharge bio-adrenomedullin levels (unadjusted).

Figure S3. Kaplan–Meier curve for 60-day rehospitalisation for tertiles of discharge bio-adrenomedullin levels (unadjusted).

Table S1. Baseline characteristics of included and excluded patients.

Table S2. Baseline characteristics according to combined groups of changes in bio-adrenomedullin levels day 1 to 7 (increase or decrease) and loop diuretic doses at discharge (high or low).

Table S3. Baseline characteristics according to groups of day 7 clinical congestion score.

Table S4. Univariable models for predictors of residual congestion at discharge.

Table S5. Multivariable model for predictors of discharge loop diuretic doses.

Table S6. Cox regression analyses for combined groups day 7 bio-adrenomedullin levels (high or low) with loop diuretic doses at discharge (high or low) for outcomes 180-day mortality and 60-day heart failure rehospitalisation.

Funding

The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Sphingotec kindly performed bio-ADM measurements.
Conflict of interest: J.S. is employed by Adrenomed AG (holds shares in the company) and Sphingotec GmbH (Sphingotec company has patent rights in commercializing the bio-ADM assay). A.B. is CSO of Adrenomed AG, CEO of Sphingotec GmbH and holds shares in both companies. J.G.C. was on the Steering Committee for the study, served on the Advisory Board for MSD, and received payments for both. M.M.G. has served on a scientific Advisory Board for Merck. M.M. has received honoraria and reimbursements from NovaCardia, sponsors of the study, and from Merck, which purchased the rights to rolofylline after completion of the PROTECT pilot study. C.M.O.C. is a consultant to Merck. J.R.T. has received research funds and consulting fees from Merck, the producer of rolofylline for the conduct of this study and has also received research funds and consulting fees from Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics, Johnson and Johnson/S bios, Novartis, Relypsa and Solvay for research in related areas. P.P. has received honoraria from Merck, G.C. and B.D. are employees of Momentum Research Inc., which was contracted to perform work on the project by Merck & Co, Inc. D.J.v.V. has received Board Membership fees or travel expenses from Arca Biopharma, Corvidia Medical, Johnson & Johnson, and Novartis. A.A.V. received consultation fees and/or research grants from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, GSK, Merck, Myokardia, Novartis, Roche Diagnostics, Servier, Sphingotec GmbH and Vifor. The other authors have nothing to disclose.

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Janowska EA, Jessup M, Linde C, Nikoyannopoulos P, Parissis JT, Pieck B, Riley JP, Rosano GM, Rutloff LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18: 891–975.

2. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Magnoni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghita M: EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013;34:383–943.

3. Al A. McNulty SE, Mentz RJ, Dunlay SM, Vador JM, AbouEzzeddine OF, De Vore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Arstom KJ, Felker GM, Hernandez AF, Stevenson LW. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARES-HF).

4. Gheorghita M, Follath F, Ponikowski P, Borsuk JH, Blair JE, Cleland JG, Dickstein K, Dzau MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, Jj MM, Filipatatos G; European Society of Cardiology; European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12: 423–433.

5. Mullens W, Danman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WH, Orso F, Rossignol P, Metra M, Filipatatos G, Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13: 137–155.

6. Voors AA, Kremer D, Geven C, ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Dingen HD, Butler J. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail 2019;21: 163–171.

7. Weber J, Scharfe J, Bergmann S, Sparwasser A, Struck J, Bergmann A. Sandwich immunosay for bioactive plasma adrenomedullin. J Appl Lab Med 2017;2:222–233.

8. ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SP, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 2019;21:732–743.

9. Kremer D, ter Maaten JM, Voors AA. Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. Eur J Heart Fail 2018;20:1363–1365.

10. Kitamura K, Kato J, Kawamoto M, Tanaka M, Chino N, Kangawa K, Eto T. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem Biophys Res Commun 1998;244;551–555.

11. Biological background bio-ADM. https://bio-adm.com/index.php?id=3 (accessed 11 November 2019).

12. Self WH, Storrow AB, Hartmann O, Barrett TW, Fermagni GJ, Maisel AS, Struck J, Bergmann A, Collins SP. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med 2016;34: 257–262.

13. Morino R, Struck J, Masiel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care 2014;18:R34.

14. Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, Cavana M, Tognoni G, Pesenti A, Gattinoni L, Masson S; ALBIOS Study Investigators. Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. Chest 2017;152:312–320.

15. Morino R, Jujie A, Navarin S, Melander O, Zoccoli G, Hartmann O, Bergmann A, Struck J, Balsus E, Di Somma S, Magnusson M. Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting. Open Heart 2019;6:e001048.

16. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Manosso GA, Bloomfield DM, Ponikowski P, O’Connor CM, Metra M, Massie BM; PROTECT Steering Committee, Investigators, and Coordinators. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rololfylline for patients hospitalized with acute decompen sated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010;16:25–35.

17. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors AA, DeLucca P, Manosso GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rololfylline, A1 adenosine receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419–1428.

18. Demissei BG, Valente MA, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors AA, DeLucca P, Manosso GA, Salerno CM, Bloomfield DM, Dittrich HC, Van Der Meer P, van Veldhuisen DJ, Hildege HL, Voors AA. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail 2016;18:269–280.

19. ter Maaten JM, Valente MA, Metra M, Bruno N, O’Connor CM, Ponikowski P, Teerlink JR, Cotter G, Metra M, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, Van Der Meer P, van Veldhuisen DJ, Hildege HL, Voors AA. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Clin Res Cardiol 2016;105:145–153.

20. Rubio-Gracia J, Demissei BG, ter Maaten J, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, Danman K, Perez-Calvo JJ, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompen sated heart failure. Int J Cardiol 2018;258:185–191.

21. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, Manosso GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, O’Connor CM. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure. Circulation 2014;130:2697–2705.

22. Francis GS, Felker GM, Tang WH. A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 2016;68: 330–337.

© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
23. Omar HR, Guglin M. A single BNP measurement in acute heart failure does not reflect the degree of congestion. *J Crit Care* 2016;33:262–265.
24. Pham D, Grodin JL. Dilemmas in the dosing of heart failure drugs: titrating diuretics in chronic heart failure. *Card Fail Rev* 2017;3:108–112.
25. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure – pathophysiology, evaluation and therapy. *Nat Rev Cardiol* 2015;12:184–192.
26. Emmens JE, ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA. Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. *Circ Heart Fail* 2019;12:e005544.
27. Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. *JACC Heart Fail* 2014;2:429–436.
28. Geven C, Bergmann A, Kox M, Pickkers P. Vascular effects of adrenomedullin and the anti-adrenomedullin antibody adrecizumab in sepsis. *Shock* 2018;50:132–140.